Standard BioTools Stock
Standard BioTools Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Country
- United States
- CEO
- Michael Egholm
- Employees
- 387
- Market cap
- $247 M
- IPO
- 10/02/2011
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through…
Standard BioTools stock: price history
1D
-4.5%
1W
-8.8%
1M
-11.3%
6M
-32.4%
YTD
-50.9%
1Y
-51.2%
2Y
-66.7%
5Y
-88.2%
10Y
-86.5%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~45% stronger price swings than usual
Ask the agents about Standard BioTools
Analyst assessment of Standard BioTools
PRICE TARGET LOW
US$3.25
CONSENSUS
US$3.25
MEDIAN
US$3.25
PRICE TARGET HIGH
US$3.25
0
STRONG BUY
6
BUY
4
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 05/11/2025
Standard BioTools stock metrics
P/E
-2.73
P/B
0.46
EV/EBITDA
-0.05
RETURN ON EQUITY
-5.0%
NET MARGIN
-133.1%
DEBT/EQUITY
0.05
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
10.9%
FLOAT SHARES
42,896,312
AVG. DAILY VOLUME (30D)
1,096,375
Insider transactions (SEC)
Mackay Sean
Kim Hanjoon Alex
Egholm Michael
Egholm Michael
Kim Hanjoon Alex
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.5%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Standard BioTools stock
What does Standard BioTools do?
Standard BioTools Inc. is a company in the Healthcare sector, Medical - Specialties industry, headquartered in United States.
The CEO is Michael Egholm, the company employs around 387 people.
The IPO was on 10/02/2011; the stock trades on NASDAQ under the ticker LAB.
What do analysts say about Standard BioTools stock?
10 analysts rate the stock, the consensus is Buy (as of 05/11/2025).
The average price target is US$3.25, ranging from US$3.25 to US$3.25, with a median of US$3.25.
This is an external assessment, not a statement by Market Jury.
When does Standard BioTools report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 45% stronger than usual.
Does Standard BioTools pay a dividend?
No, Standard BioTools currently does not pay a dividend.
Which stocks are comparable to Standard BioTools?
Comparable stocks include STERIS, QuidelOrtho, Mesa Laboratories, 908 Devices, Trinity Biotech, Eli Lilly and Company, Johnson & Johnson and AbbVie.
How can I get Standard BioTools stock analyzed?
Clicking "Analyze stock" lets five strategies assess Standard BioTools against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.